Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee
Authors:
- Aaron R. WeissAWAaron R. Weiss
- Elizabeth R. LydenELElizabeth R. Lyden
- James R. AndersonJAJames R. Anderson
- Douglas S. HawkinsDHDouglas S. Hawkins
- Sheri L. SpuntSSSheri L. Spunt
- David O. WalterhouseDWDavid O. Walterhouse
- Suzanne L. WoldenSWSuzanne L. Wolden
- David M. ParhamDPDavid M. Parham
- David A. RodebergDRDavid A. Rodeberg
- Simon C. KaoSKSimon C. Kao
- Richard B. WomerRWRichard B. Womer
- 10 September 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (26) , 3226-3232
Abstract
Purpose: To simplify the recommended staging evaluation by correlating tumor and clinical features with patterns of distant metastasis in newly diagnosed patients with embryonal rhabdomyosarcoma (ERMS) or alveolar rhabdomyosarcoma (ARMS). Patients and Methods: Patient data from the Intergroup Rhabdomyosarcoma Study Group and the Children's Oncology Group over two periods were analyzed: 1991 to 1997 and 1999 to 2004. We used recursive partitioning analyses to identify factors (including histology, age, regional nodal and distant metastatic status, tumor size, local invasiveness, and primary site) that divided patients into subsets with the most different rates of metastatic disease. Results: Of the 1,687 patients analyzed, 5.7% had lung metastases, 4.8% had bone involvement, and 6% had bone marrow (BM) involvement. Rhabdomyosarcoma (RMS) without local invasion (T1) had a low rate of metastasis for all distant sites, especially ERMS (0% bone, 0% BM). ARMS with local invasion (T2) had a higher rate of metastasis for all distant sites (13% lung, 18% bone, 23% BM). ERMS, T2 also had a higher rate of metastatic lung involvement (9%). The likelihood of bone or BM involvement increased in the presence of lung metastases (41% with, 6% without). Regional nodal metastases (N1) predicted a high rate of metastasis in all distant sites (14% lung, 14% bone, 18% BM). A staging algorithm was developed. Conclusion: Staging studies in childhood RMS can be tailored to patients' presenting characteristics. Bone marrow aspirate and biopsy and bone scan are unnecessary in at least one third of patients with RMS.Keywords
This publication has 32 references indexed in Scilit:
- Additional Benefit of F-18 FDG PET/CT in the Staging and Follow-up of Pediatric RhabdomyosarcomaClinical Nuclear Medicine, 2011
- Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology GroupJournal of Clinical Oncology, 2011
- Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803Journal of Clinical Oncology, 2009
- Radiation risks from imaging studies in children with cancerPediatric Blood & Cancer, 2008
- Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft‐tissue sarcomaPediatric Blood & Cancer, 2008
- Initial Patient Characteristics Can Predict Pattern and Risk of Relapse in Localized RhabdomyosarcomaJournal of Clinical Oncology, 2008
- Rhabdomyosarcoma With Widespread Bone Marrow InfiltrationClinical Nuclear Medicine, 2007
- Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology GroupJournal of Clinical Oncology, 2007
- Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children With Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children’s Oncology Group StudyJournal of Clinical Oncology, 2004
- Age is an independent prognostic factor in rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology groupPediatric Blood & Cancer, 2003